DOP Session 6

DOP46-54

  • 17:05-18:05 Digital Oral Presentation Session 6 - Novel Treatments
    Room: C1-M4-5, Hall C, Bella Center
    Chairs: Marc Ferrante, Leuven, Belgium
    Gionata Fiorino, Rome, Italy
      17:05-17:11 DOP46: Extended induction treatment with mirikizumab in patients with Moderately to Severely Active Ulcerative Colitis: Results from a phase 2 trial
    W. J. Sandborn1, M. Ferrante2, B. R. Bhandari3, E. Berliba4, T. Hibi5, G. Geert R. D'Haens6, J. Tuttle7, K. Krueger8, S. Friedrich8, M. Durante8, V. Arora8, B. Feagan9
    1
    University California San Diego, La Jolla, California, United States, 2UZ Leuven, KU Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium, 3Delta Research Partners, LLC, Bastrop, LA, United States, 4Nicolae Testemițanu State University of Medicine and Pharmacy, Chisinau, Moldova, Republic of, 5Kitasato Institute Hospital Center for Advanced IBD Research and Treatment, Minato-ku, Tokyo, Japan, 6Amsterdam University Medical Centers, Amsterdam, Netherlands, 7Eli Lilly and Company, Lilly Biotechnology Center, San Diego, California, United States, 8Eli Lilly and Company, Indianapolis, Indiana, United States, 9Western University, Robarts Clinical Trials Inc, London, Ontario, Canada  
      17:11-17:17 DOP47: Sustained remission in patients with Moderate to Severe Ulcerative Colitis: Results from the phase 3 UNIFI maintenance study
    G. Van Assche1, S. R. Targan2, T. Baker3, C. D. O'Brien3, H. Zhang3, J. Johanns3, P. Szapary3, C. Marano3, R. W. Leong4, 5, D. Rowbotham6, 7, T. Hisamatsu8, S. Danese9, B. E. Sands10, L. Peyrin-Biroulet11
    1
    University of Leuven, Leuven, Belgium, 2Cedars-Sinai Medical Center, Los Angeles, United States, 3Janssen Research and Development, Spring House, United States, 4Concord Hospital, Sydney, Australia, 5Macquarie University Hospital, Sydney, Australia, 6Auckland City Hospital, Auckland, New Zealand, 7University of Auckland, Auckland, New Zealand, 8Kyorin University, Tokyo, Japan, 9Humanitas Research Hospital, Milan, Italy, 10Icahn School of Medicine at Mount Sinai, New York, United States, 11Nancy University Hospital, Vandœuvre-lès-Nancy, France
      17:17-17:23 DOP48: Amiselimod, a selective S1P receptor modulator in Crohn's Disease patients: A proof of concept study
    G. D'Haens1, S. Danese2, M. Davies3, M. Watanabe4, T. Hibi5
    1
    Academic Medical Centre, Amsterdam, Netherlands, 2Humanitas Research Hospital, Gastroenterology, Milano, Italy, 3Mitsubishi Tanabe Europe Ltd, London, United Kingdom, 4Tokyo Medical and Dental University, Gastroenterology, Tokyo, Japan, 5University Kitasato Hospital, Gastroenterology, Tokyo, Japan
      17:23-17:29 DOP49: Efficacy of the anti-mucosal addressin cell adhesion molecule-1 (MAdCAM-1) antibody SHP647 in Ulcerative Colitis: Results from the open-label extension study TURANDOT II
    W. Reinisch1, W. J. Sandborn2, S. Danese3, X. Hébuterne4, M. Kłopocka5, D. Tarabar6, T. Vaňásek7, M. Greguš8, P. A. Hellstern9, J. S. Kim10, M. Sparrow11, K. J. Gorelick12, M. Goetsch13, C. Bliss14, C. Gupta15, F. Cataldi14, S. Vermeire16
    1
    Medical University of Vienna, Vienna, Austria, 2University of California San Diego, La Jolla, CA, United States, 3Humanitas University, Milan, Italy, 4University of Nice Sophia Antipolis, Hospital l'Archet, Nice, France, 5Nicolaus Copernicus University, Collegium Medicum in Bydgoszcz, Bydgoszcz, Poland, 6Clinic of Gastroenterology and Hepatology, Military Medical Academy, Belgrade, Serbia, 7Charles University Hospital, Hradec Králové, Czech Republic, 8Gastroenterology Center, Nitra, Slovakia, 9Nature Coast Clinical Research, Inverness, FL, United States, 10Seoul National University College of Medicine, Seoul, South Korea, 11Alfred Hospital, Melbourne, VIC, Australia, 12Zymo Consulting Group, Newtown Square, PA, United States, 13Shire, Zug, Switzerland, 14Shire, Lexington, MA, United States, 15Cytel Inc., Cambridge, MA, United States, 16University Hospitals Leuven, Leuven, Belgium
      17:29-17:35 DOP50: Effect of upadacitinib on extra-intestinal manifestations in patients with Moderate to Severe Crohn’s Disease: Data from the CELEST study
    L. Peyrin-Biroulet1, S. Danese2, E. Louis3, P. D.R. Higgins4, M. Dubinsky5, F. Cataldi6, Q. Zhou6, W.-J. Lee6, K. Kligys6, A. P. Lacerda6
    1University of Lorraine, Nancy, France, 2Istituto Clinico Humanitas, Milan, Italy, 3CHU de Liège et Université de Liège, Liège, Belgium, 4University of Michigan, Ann Arbor, United States, 5Icahn School of Medicine at Mount Sinai, New York, United States, 6AbbVie Inc., North Chicago, United States
      17:35-17:41 DOP51: Biomarker and pharmacokinetic data from the TURANDOT II open-label extension study of the anti-mucosal addressin cell adhesion molecule-1 (MAdCAM-1) antibody SHP647 in patients with Ulcerative Colitis
    W. Reinisch1, W. J. Sandborn2, S. Danese3, X. Hébuterne4, M. Kłopocka5, D. Tarabar6, T. Vaňásek7, M. Greguš8, P. A. Hellstern9, J. S. Kim10, M. Sparrow11, K. J. Gorelick12, M. Goetsch13, C. Bliss14, C. Gupta15, F. Cataldi14, S. Vermeire16
    1
    Medical University of Vienna, Vienna, Austria, 2University of California San Diego, La Jolla, CA, United States, 3Humanitas University, Milan, Italy, 4University of Nice Sophia Antipolis, Hospital l'Archet, Nice, France, 5Nicolaus Copernicus University, Collegium Medicum in Bydgoszcz, Bydgoszcz, Poland, 6Clinic of Gastroenterology and Hepatology, Military Medical Academy, Belgrade, Serbia, 7Charles University Hospital, Hradec Králové, Czech Republic, 8Gastroenterology Center, Nitra, Slovakia, 9Nature Coast Clinical Research, Inverness, FL, United States, 10Seoul National University College of Medicine, Seoul, South Korea, 11Alfred Hospital, Melbourne, VIC, Australia, 12Zymo Consulting Group, Newtown Square, PA, United States, 13Shire, Zug, Switzerland, 14Shire, Lexington, MA, United States, 15Cytel Inc., Cambridge, MA, United States, 16University Hospitals Leuven, Leuven, Belgium
      17:41-17:47 DOP52: Reduction in inflammatory biomarkers in a phase 2 study of mirikizumab in patients with Moderately to Severely Active Ulcerative Colitis
    W. J. Sandborn1, B. Sands2, T. Kobayashi3, J. Tuttle4, J. Schmitz5, M. Durante5, R. Higgs5, J. B. Canavan5, R. Siegel5, M. Ferrante6
    1
    University California San Diego, La Jolla, California, United States, 2Mount Sinai Health System, Icahn School of Medicine at Mount Sinai, New York, New York, United States, 3Kitasato University, Center for Advanced IBD Research and Treatment, Tokyo, Japan, 4Eli Lilly and Company, Lilly Biotechnology Center, San Diego, California, United States, 5Eli Lilly and Company, Indianapolis, Indiana, United States, 6UZ Leuven, KU Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium
      17:47-17:53 DOP53: Clinical, endoscopic, histologic and biomarker activity following treatment with the gut-selective, pan-JAK Inhibitor TD-1473 in Moderately to Severely Active Ulcerative Colitis
    W. Sandborn1, D. Nguyen2, B. Ferslew2, L.-Y. Hao3, T. Kanno3, L. Tomsho3, D. Boyle1, R. Graham2, B. Abhyankar2, J. Panes4
    1
    University of California San Diego, Medicine, San Diego, United States, 2Theravance Biopharma US, Inc, South San Francisco, United States, 3Janssen R&D, Springhouse, United States, 4Hospital Clinic Barcelona, Gastroenterology, Barcelona, Spain
      17:53-17:59 DOP54: Efficacy and safety of ustekinumab through week 16 in patients with Moderate to Severe Ulcerative Colitis randomised to ustekinumab: Results from the UNIFI induction trial
    S. Danese1, B. E. Sands2, C. D. O'Brien3, H. Zhang3, J. Johanns3, S. Sloan3, J. Izanec4, P. Szapary3, C. Marano3, R. W. Leong5, 6, D. Rowbotham7, 8, S. R. Targan9, G. Van Assche10
    1
    Humanitas Research Hospital, Milan, Italy, 2Icahn School of Medicine at Mount Sinai, New York, United States, 3Janssen Research & Development, LLC, Spring House, United States, 4Janssen Scientific Affairs, LLC, Horsham, United States, 5Concord Hospital, Sydney, Australia, 6Macquarie University Hospital, Sydney, Australia, 7Auckland City Hospital, Auckland, New Zealand, 8University of Auckland, Auckland, New Zealand, 9Cedars-Sinai Medical Center, Los Angeles, United States, 10University of Leuven, Leuven, Belgium

Digital Oral Presentations
(as of January 2019)

  • DOP Session 1 Advances in IBD pathophysiology
    DOP01-09
    Room: C1 M1
    Chairs: Javier Gisbert, Madrid, Spain
    Maximilian Waldner, Erlangen, Germany
    DOP Session 2 Mechanisms of intestinal inflammation
    DOP10-18
    Room: C1 M0
    Chairs: Loris Riccardo Lopetuso, Rome, Italy
    Britta Siegmund, Berlin, Germany
    DOP Session 3 Translational science in IBD
    DOP19-27
    Room: C1 M2
    Chairs: Peter Bossuyt, Bonheiden, Belgium
    Axel Dignass, Frankfurt, Germany
    DOP Session 4 Practicalities of IBD patient care
    DOP28-36
    Room: C1 M3
    Chairs: Uri Kopylov, Tel Aviv, Israel
    Fernando Magro, Porto, Portugal
    DOP Session 5 Old and new treatment
    DOP37-45
    Room: C1 M4-5
    Chairs: Paolo Gionchetti, Bologna, Italy
    Anne Strik, Amsterdam, The Netherlands
  • DOP Session 6 Novel treatments
    DOP46-54
    Room C1 M4-5
    Chairs: Marc Ferrante, Leuven, Belgium
    Gionata Fiorino, Rome, Italy
    DOP Session 7 Recent advances of biologic therapies
    DOP55-63
    Room: C1 M3
    Chairs: Filip Baert, Roeselare, Belgium
    Shomron Ben-Horin, Ramat Gan, Israel
    DOP Session 8 Intestinal healing
    DOP64-72
    Room: C1 M2
    Chairs: Raja Atreya, Erlangen, Germany
    Marietta Iacucci, Birmingham, United Kingdom
    DOP Session 9 Surgery and IBD
    DOP73-81
    Room: C1 M1
    Chairs: Paulo Kotze, Curitiba, Brazil
    Andre D'Hoore, Leuven, Belgium
    DOP Session 10 Clinical epidemiology
    DOP82-90
    Room: C1 M0
    Chairs: Stefanos Bonovas, Milan, Italy
    Johan Burisch, Copenhagen, Denmark